Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2010 Jul-Aug;2(4):449-56.
doi: 10.4161/mabs.12305. Epub 2010 Jul 1.

Phase I trial of a humanized, Fc receptor nonbinding anti-CD3 antibody, hu12F6mu in patients receiving renal allografts

Jing Li  1 , Bo Zhou  1 , Jianzhong Shentu  2 , Li Du  3 , Min Tan  3 , Sheng Hou  1 , Weizhu Qian  1 , Bohua Li  1 , Dapeng Zhang  1 , Jianxin Dai  1 , Hao Wang  1 , Xu Zhang  4 , Jianghua Chen  2 , Yajun Guo  1
Affiliations
Clinical Trial

Phase I trial of a humanized, Fc receptor nonbinding anti-CD3 antibody, hu12F6mu in patients receiving renal allografts

Jing Li et al. MAbs. 2010 Jul-Aug.

Abstract

Hu12F6mu is an Fc-mutated, humanized anti-CD3 antibody developed in our lab. The aim of this study was to assess single dose escalation pharmacokinetics (PK) and safety profile of hu12F6mu and to measure the effects of the antibody on levels of circulating T cells over time. Twenty-seven patients receiving renal allografts were randomized to receive hu12F6mu intravenously at a single-dose of 2.5, 5 or 10 mg. The concentration-time data obtained by a validated ELISA method were subjected to non-compartmental PK analysis by DAS 2.1 software. Subgroups of CD2(+), CD3(+), CD4(+) and CD8(+) lymphocytes were monitored periodically by flow cytometry. Our results showed that hu12F6mu exhibited linear PK over the dose range of 2.5 to 10 mg. A significant decline in the proportion of T cells was observed immediately after the infusion, followed by a progressive increase occurring over the ensuing days of therapy. A significant negative correlation was observed between serum concentration of hu12F6mu and CD3(+) cell proportion. Intravenous infusion of hu12F6mu was well-tolerated in patients receiving renal allografts. These results suggest that hu12F6mu may have potential as a therapeutic agent, although further studies are needed.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Concentration-time curves of hu12F6mu after a single intravenous infusion of 2.5 mg (■, n = 9), 5 mg (●, n = 9) and 10 mg (▲, n = 9) antibody in kidney transplantation recipients. Data are expressed as mean ± SD.
Figure 2
Figure 2
Mean proportion (%) of CD2+ subset in three groups. Data represent mean ± SD values for different subjects in 2.5 mg (■, n = 9), 5 mg (●, n = 9) and 10 mg (▲, n = 9) group.
Figure 3
Figure 3
Mean proportion (%) of CD3+ subset in three groups. Data represent mean ± SD values for different subjects in 2.5 mg (■, n = 9), 5 mg (●, n = 9) and 10 mg (▲, n = 9) group.
Figure 4
Figure 4
Mean proportion (%) of CD4+ subset in three groups. Data represent mean ± SD values for different subjects in 2.5 mg (■, n = 9), 5 mg (●, n = 9) and 10 mg (▲, n = 9) group.
Figure 5
Figure 5
Mean proportion (%) of CD8+ subset in three groups. Data represent mean ± SD values for different subjects in 2.5 mg (■, n = 9), 5 mg (●, n = 9) and 10 mg (▲, n = 9) group.
Figure 6
Figure 6
Mean blood lymphocyte counts (×109/L) in three groups. Data represent mean ± SD values for different subjects in 2.5 mg (■, n = 9), 5 mg (●, n = 9) and 10 mg (▲, n = 9) group.
Figure 7
Figure 7
The concentration-effect plots display the coherence between hu12F6mu serum concentration and CD3+ cell proportion (%) after administration of 10 mg of antibody. ■, CD3+ proportion (%); ●, hu12F6mu serum concentration (ng·L−1).
See this image and copyright information in PMC

References

    1. Cosimi AB. Clinical development of Orthoclone OKT3. Transplant Proc. 1987;19:7–16. - PubMed
    1. Colonna JO, Goldstein LI, Brems JJ, Vargas JH, Brill JE, Berquist WJ, et al. A prospective study on the use of monoclonal anti-T3-cell antibody (OKT3) to treat steroid-resistant liver transplant rejection. Arch Surg. 1987;112:1120–1123. - PubMed
    1. Cosimi AB, Burton RC, Colvin RB, Goldstein G, Delmonico FL, LaQuaglia MP, et al. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation. 1981;32:535–539. - PubMed
    1. Cosimi AB, Cho SI, Delmonico FL, Kaplan MM, Rohrer RJ, Jenkins RL. A randomized clinical trial comparing OKT3 and steroids for treatment of hepatic allograft rejection. Transplantation Proc. 1987;19:2431–2433. - PubMed
    1. Delmonico FL, Auchincloss H, Yang H, Russell PS, Cosimi AB. Indications and outcome of OKT3 therapy after liver, pancreas and renal transplantation. Transplant Proc. 1988;20:249–252. - PubMed

Publication types

MeSH terms